Streamlined, automated solution for analysis and quantification of PET FDG and beta amyloid brain scans.

PET brain imaging can be a critical tool in the workup of complex neurodegenerative diseases especially those diseases that impact patients cognitive function. With the introduction of beta amyloid specific tracers into clinical practice there is now a need for your department to be skilled for interpretation of both FDG and beta amyloid tracer image analysis. CortexID Suite can assist with accurate, consistent quantitative results and present the information in a manner custom designed for referring physicians and patients.

Overview
CortexID Suite supports data acquired on PET and hybrid PET scanners. It is a fully automated, post processing software solution capable of quantifying PET FDG and beta amyloid brain scans. CortexID Suite may aid physicians in the interpretation process of PET studies conducted on patients being evaluated for cognitive impairment, or other causes of cognitive decline, and is an adjunct to other diagnostic evaluations.

What’s new
- Quantitative analysis for beta amyloid PET tracers.
- Correlate structure and function with PET-MR registration.
- Proven robust analysis method.
- Enhanced FDG Normals database
- Quantitative longitudinal comparisons.
- Exam Summary tool for streamlined communications
- Q.Check enabling quality control for quantitation
- Dynamic Summing

Visit us: www.gehealthcare.com/aw/applications/cortex-id/
Features

• Supports visual and quantitative assessment of PET brain FDG and beta amyloid images.
• PET-MR registration allowing functional findings to be correlated to patient anatomy.
• Proprietary, adaptive template registration technique with anatomic normalization to a standardized space.
• 3D SSP models for uptake ratio and Z-score images.

• Quantitative comparison of longitudinal studies
• Referring physician and patient based exam summary reports for streamlining communication of results.
• Customizable interface
• Q.Check highlights acquisition parameters that differ from the expected values
• Dynamic summing
• Easy exporting capability of results

PET only based quantitation. Not dependent on MR to deliver quantitative analysis.
Predefined regions optimized for FDG and beta amyloid analysis
Regional quantitative results

Comparison with normals databases for FDG F 18, flutemetamol F 18 and PiB* C 11.

System Requirements
CortexID Suite is compatible with:
• GE Advantage Workstation 4.6 and later
• AW Server 3.1 and later.

Indications for Use
CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism.

CortexID Suite additionally allows the user to generate information in PET brain amyloid load between a subject’s images and a normal database, which may be the result of brain neurodegeneration. PET co-registration and fusion display capabilities with CT and MR allow PET findings to be related to brain anatomy and offers visualization of structural abnormalities, which may result from brain injury, trauma, disorder, disease or dysfunction, such as subdural hematoma, tumor, stroke, or cerebrovascular disease, etc.

CortexID Suite may aid physicians in the image interpretation process of PET studies conducted on patients being evaluated for cognitive impairment, or other causes of cognitive decline, and is an adjunct to other diagnostic evaluations.

Regulatory Compliance
This product complies with the following requirements:

Access to PiB normal database may vary by region.